Cited by CrossRef (13)

  1. Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinol Metab 2020;35:329
    https://doi.org/10.3803/EnM.2020.35.2.329
  2. Siwen Wang, Ting Wu, Zhihong Zuo, Ping Jin, Xuan Luo, Meichun Deng. Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis. 2022;28:1840
    https://doi.org/10.1093/eurjpc/zwab099
  3. Ryaan EL-Andari, Nicholas M. Fialka, Jimmy Kang, Sabin J. Bozso, Jayan Nagendran, Jeevan Nagendran. The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review. Am J Cardiovasc Drugs 2024;24:55
    https://doi.org/10.1007/s40256-023-00618-0
  4. Panagiotis Theofilis, Alexios S. Antonopoulos, Themistoklis Katsimichas, Evangelos Oikonomou, Gerasimos Siasos, Constantina Aggeli, Konstantinos Tsioufis, Dimitris Tousoulis. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacological Research 2022;180:106243
    https://doi.org/10.1016/j.phrs.2022.106243
  5. Andrea Natali, Lorenzo Nesti, Domenico Tricò, Ele Ferrannini. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol 2021;20
    https://doi.org/10.1186/s12933-021-01385-5
  6. Milijana Janjusevic, Alessandra Lucia Fluca, Giulia Gagno, Alessandro Pierri, Laura Padoan, Annamaria Sorrentino, Antonio Paolo Beltrami, Gianfranco Sinagra, Aneta Aleksova. Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. IJMS 2022;23:2336
    https://doi.org/10.3390/ijms23042336
  7. In-Chang Hwang, Goo-Yeong Cho, Yeonyee E. Yoon, Jin Joo Park, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim, Dae-Won Sohn. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol 2020;19
    https://doi.org/10.1186/s12933-020-01042-3
  8. William Hinton, Abdus Samad Ansari, Martin B. Whyte, Andrew P. McGovern, Michael D. Feher, Neil Munro, Simon de Lusignan. Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies. Diabetes Obesity Metabolism 2023;25:501
    https://doi.org/10.1111/dom.14893
  9. Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Domenico Trico, Angela Dardano, Simona Baldi, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello, Andrea Natali. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol 2022;21
    https://doi.org/10.1186/s12933-022-01618-1
  10. Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol 2021;20
    https://doi.org/10.1186/s12933-021-01228-3
  11. Yakov F. Zverev, Anna Y. Rykunova. Direct cardial effects and mechanisms of cardiovascular action of gliflosins. Rev Clin Pharm Drug Ther 2021;19:131
    https://doi.org/10.17816/RCF192131-143
  12. Petra Grubić Rotkvić, Ivana Ćelap, Valerija Bralić Lang, Juraj Jug, Andrea Snagić, Ivana Huljev Šipoš, Maja Cigrovski Berković. Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease. Journal of Diabetes and its Complications 2023;37:108541
    https://doi.org/10.1016/j.jdiacomp.2023.108541
  13. Sharif A. Sabe, Dwight D. Harris, Mark Broadwin, Cynthia M. Xu, Mohamed Sabra, Debolina Banerjee, M. Ruhul Abid, Frank W. Sellke. Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium. Vessel Plus 2024
    https://doi.org/10.20517/2574-1209.2023.95